THE INDUSTRY’S LARGEST MARKETPLACE FOR PHARMACEUTICALS
steroidify.xyz has been in operation for almost 30 years, acquiring 50’s of thousands of satisfied customers.
steroidify.xyz works very hard to establish trust with our customer. Our high-quality products and professional staff is testament to the legitimacy of our business practice.
Each brand is hand-selected and goes through a very thorough review process.
Quality is held in a very high regard at steroidify.xyz. To further legitimize these products, we do have a comprehensive
Featured
Acro-Trestolone (Ment)
ACTIVE HALF-LIFE 8-12 hours CLASSIFICATION Anabolic Steroid DOSAGE 50 mg/day ACNE Rarely WATER RETENTION N..
SuperTest 450 Blend
ACTIVE HALF-LIFE 7-8 Days CLASSIFICATION Anabolic Steroid DOSAGE Recommended for Men: 400-1200 mg/week ACNE Potentia..
Susta 250
ACTIVE HALF-LIFE 7-8 Days CLASSIFICATION Anabolic Steroid DOSAGE Men 300-1500 mg/week ACNE Yes WATER RETENTION..
Ketosteril
ACNE No WATER RETENTION No HBR No HEPATOTOXICITY No AROMATIZATION No MANUFACTURER ..
Testosterone-Equipoise Blend 400
ACTIVE HALF-LIFE 14-16 days CLASSIFICATION Anabolic Steroid DOSAGE Recommended for men: 250-600 mg/week ACNE ..
Mastermed E 200
ACTIVE HALF-LIFE 4.5-5 days CLASSIFICATION Anabolic Steroid DOSAGE Men: 300-700 mg/week ACNE Yes W..
Ultima-Hexarelin 5mg
MANUFACTURER Ultima Peptides WAREHOUSE International Warehouse 3 SUBSTANCE Examorelin Discover the power of..
Ultima-Femara
ACTIVE HALF-LIFE 2 days CLASSIFICATION Non-Steroidal Aromatase Inhibitor DOSAGE 5 mg/day ACNE No WATER RETENTI..
Divator 10
MANUFACTURER Drogsan WAREHOUSE International Warehouse 2 ACTIVE INGREDIENT Atorvastatin..
Anomass 400 Mix
ACTIVE HALF-LIFE 14 days CLASSIFICATION Anabolic Steroid DOSAGE Recommended for men: 400-700 mg/week ACNE Rarely exp..
Cypo-Testosterone 200
ACTIVE HALF-LIFE 7-8 Days CLASSIFICATION Anabolic Steroid DOSAGE Men: 300-1500 mg/week ACNE Yes WATER RETENTIO..
Provixin
ACTIVE HALF-LIFE 12 hours CLASSIFICATION Anabolic Steroid DOSAGE Men: 25-100 mg/day ACNE Yes WATER RETENTION ..












